UPMC HIllman Cancer Center Neuro Oncology Clinical Studies

Brain and Nervous System Cancer Clinical Trials and Research

Doctors at UPMC Hillman Cancer Center work with top scientists across the U.S. to:

  • Advance research into promising new treatments for brain and nervous system cancers.
  • Study more people in each trial so we can learn faster.
  • Gives people who come to UPMC Hillman for care access to more trials.

All brain cancer treatments we use now are the result of past clinical trials.

At UPMC, we invest in cancer research because we want to improve survival rates and quality of life for people.

Current Brain and Nervous System Tumor Trials

Doctors at UPMC Hillman's Neuro-Oncology Program are leading more than 15 studies. Click on any trial's number to see details on the U.S. National Institutes of Health (NIH) clinical trials website.

An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL).

GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM).

 Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM (EF-32).

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Recurrent Glioblastoma.

A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination with Radiation Therapy in Patients with Glioblastoma Multiforme.

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden.

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers.

Olaparib in Treating Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations.

 Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment.

 NRG-BN010, A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma.

 Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas.

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma.

An interventional, non-randomized, phase 1/2, light-dose-escalation study to investigate the safety and feasibility of intraoperative photodynamic therapy (PDT) with Pentalafen® drug and Heliance® Solution device in male and female patients 18 to 69 years of age with grade IV glioblastoma.

 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System (CNS) Tumors Harboring Activating FGFR 1-3 Alterations (FIGHT-209).

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma.

Contact the Neuro-Oncology Program to Make an Appointment

To learn more about brain and nervous system cancer or to make an appointment, you can:

Fill out our online contact form.